Key Highlights
- Exopharm has a new Investor Presentation available to shareholders and investors on our website
- 2 lead Genetic Medicine (GM) programs have been selected for our in-house product development investment
- These products have been selected considering potential future commercial value and as a way to showcase exosomes as a non-viral nanoparticle ‘chassis’ to overcome drug-delivery problems that GMs face
- Genetic Medicines (GMs) (e.g. mRNA, DNA and CRISPR) are an emerging part of modern-medicines and hold great promise to address unmet medical need